Thematische Bibliographien / Breast cancer, microRNAs, miR-106b

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Konferenzberichte

Auswahl der wissenschaftlichen Literatur zum Thema „Breast cancer, microRNAs, miR-106b“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 6. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Breast cancer, microRNAs, miR-106b" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Breast cancer, microRNAs, miR-106b"

Andrikopoulou, Angeliki, Almog Shalit, Eleni Zografos, Konstantinos Koutsoukos, Anna-Maria Korakiti, Michalis Liontos, Meletios-Athanasios Dimopoulos und Flora Zagouri. „MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment“. Cancers 13, Nr. 16 (16.08.2021): 4114. http://dx.doi.org/10.3390/cancers13164114.

Der volle Inhalt der Quelle

Annotation:

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have emerged as novel treatment options in the management of advanced or metastatic breast cancer. MicroRNAs are endogenous non-coding 19–22-nucleotide-long RNAs that regulate gene expression in development and tumorigenesis. Herein, we systematically review all microRNAs associated with response to CDK4/6 inhibitors in solid tumors and hematological malignancies. Eligible articles were identified by a search of the MEDLINE and ClinicalTrials.gov databases for the period up to1 January 2021; the algorithm consisted of a predefined combination of the words “microRNAs”, “cancer” and “CDK 4/6 inhibitors”. Overall, 15 studies were retrieved. Six microRNAs (miR-126, miR-326, miR3613-3p, miR-29b-3p, miR-497 and miR-17-92) were associated with sensitivity to CDK4/6 inhibitors. Conversely, six microRNAs (miR-193b, miR-432-5p, miR-200a, miR-223, Let-7a and miR-21) conferred resistance to treatment with CDK4/6 inhibitors. An additional number of microRNAs (miR-124a, miR9, miR200b and miR-106b) were shown to mediate cellular response to CDK4/6 inhibitors without affecting sensitivity to treatment. Collectively, our review provides evidence that microRNAs could serve as predictive biomarkers for treatment with CDK4/6 inhibitors. Moreover, microRNA-targeted therapy could potentially maximize sensitivity to CDK4/6 inhibition.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kalniete, Dagnija, Miki Nakazawa-Miklasevica, Ilze Strumfa, Arnis Abolins, Arvids Irmejs, Genadijs Trofimovics, Janis Gardovskis und Edvins Miklasevics. „MicroRNA Expression in Different Sybtypes of Breast Cancer“. Acta Chirurgica Latviensis 13, Nr. 1 (01.12.2013): 7–12. http://dx.doi.org/10.2478/chilat-2013-0002.

Der volle Inhalt der Quelle

Annotation:

Summary Introduction. MicroRNAs are a class of small, non-coding RNA molecules able to regulate gene expression at the post-transcriptional level through binding to the 3’-UTR of the targeted mRNA, thus suppressing translation of the mRNA. In various diseases, including malignancies, expression of microRNAs is altered. Moreover, the altered expression of the microRNAs correlates with clinical and pathophysiological features of cancer thus making them good candidates for prognostic/predictive markers. Aim of the study. The aim of this study was to determine expression level of five different microRNAs (miR-10b, miR-21, miR-29a, miR-31, and miR-214) in breast cancer tissues and to look for the differences in microRNA expression between distinct subtypes of breast cancer. Material and methods. Forty five breast cancer and corresponding resection line tissues (control tissues) were studied. Breast cancer tissues were classified into the subtypes of triple-negative (23), luminal-A (13), luminal-B (7), and HER2+ (2). Quantitative analysis of miR-10b, miR-21, miR-29a, miR-31, and miR-214 was performed by real-time PCR. The expression levels of microRNAs were normalized by the expression of the reference gene RNU6B. The event-free survival in regard of high and low expression levels of microRNAs were analyzed by Log-rank (Mantel Cox) and Gehan-Breslow-Wilcoxon tests. Results. Expression levels of four microRNAs (miR-21, miR-29a, miR-31, and miR-214) were significantly higher in cancer tissues than in corresponding resection line tissues. Breast cancer patients with low expression level of miR-21 showed a trend of better event-free survival than breast cancer patients with high expression level of miR-21; however, this trend did not reach statistical significance. In triple-negative tumor tissues, miR-21, miR-29a, and miR-31 showed significantly higher expression level than in luminal-A tumor tissues. Expression levels of miR-21 and miR-29a were significantly higher in triple-negative tumor tissues than in luminal-B tumor tissues. Conclusions. Breast cancer patients with high expression level of miR-21 in tumor tissues show a trend of worse event-free survival, though; this trend did not reach statistical significance. Different microRNA expression in distinct subtypes of breast cancer points to the genetic heterogeneity of breast cancer, different regulatory targets and signaling pathways

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Matamala, Nerea, María Teresa Vargas, Ricardo González-Cámpora, Rebeca Miñambres, José Ignacio Arias, Primitiva Menéndez, Eduardo Andrés-León et al. „Tumor MicroRNA Expression Profiling Identifies Circulating MicroRNAs for Early Breast Cancer Detection“. Clinical Chemistry 61, Nr. 8 (01.08.2015): 1098–106. http://dx.doi.org/10.1373/clinchem.2015.238691.

Der volle Inhalt der Quelle

Annotation:

Abstract BACKGROUND The identification of novel biomarkers for early breast cancer detection would be a great advance. Because of their role in tumorigenesis and stability in body fluids, microRNAs (miRNAs) are emerging as a promising diagnostic tool. Our aim was to identify miRNAs deregulated in breast tumors and evaluate the potential of circulating miRNAs in breast cancer detection. METHODS We conducted miRNA expression profiling of 1919 human miRNAs in paraffin-embedded tissue from 122 breast tumors and 11 healthy breast tissue samples. Differential expression analysis was performed, and a microarray classifier was generated. The most relevant miRNAs were analyzed in plasma from 26 healthy individuals and 83 patients with breast cancer (36 before and 47 after treatment) and validated in 116 healthy individuals and 114 patients before treatment. RESULTS We identified a large number of miRNAs deregulated in breast cancer and generated a 25-miRNA microarray classifier that discriminated breast tumors with high diagnostic sensitivity and specificity. Ten miRNAs were selected for further investigation, of which 4 (miR-505-5p, miR-125b-5p, miR-21-5p, and miR-96-5p) were significantly overexpressed in pretreated patients with breast cancer compared with healthy individuals in 2 different series of plasma. MiR-505-5p and miR-96-5p were the most valuable biomarkers (area under the curve 0.72). Moreover, the expression levels of miR-3656, miR-505-5p, and miR-21-5p were decreased in a group of treated patients. CONCLUSIONS Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Adam-Artigues, Anna, Iris Garrido-Cano, Juan Antonio Carbonell-Asins, Ana Lameirinhas, Soraya Simón, Belén Ortega-Morillo, María Teresa Martínez et al. „Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer“. Cancers 13, Nr. 11 (07.06.2021): 2848. http://dx.doi.org/10.3390/cancers13112848.

Der volle Inhalt der Quelle

Annotation:

The early diagnosis of breast cancer is essential to improve patients’ survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Vimalraj, S., P. J. Miranda, B. Ramyakrishna und N. Selvamurugan. „Regulation of Breast Cancer and Bone Metastasis by MicroRNAs“. Disease Markers 35 (2013): 369–87. http://dx.doi.org/10.1155/2013/451248.

Der volle Inhalt der Quelle

Annotation:

Breast cancer progression including bone metastasis is a complex process involving numerous changes in gene expression and function. MicroRNAs (miRNAs) are small endogenous noncoding RNAs that regulate gene expression by targeting protein-coding mRNAs posttranscriptionally, often affecting a number of gene targets simultaneously. Alteration in expression of miRNAs is common in human breast cancer, possessing with either oncogenic or tumor suppressive activity. The expression and the functional role of several miRNAs (miR-206, miR-31, miR-27a/b, miR-21, miR-92a, miR-205, miR-125a/b, miR-10b, miR-155, miR-146a/b, miR-335, miR-204, miR-211, miR-7, miR-22, miR-126, and miR-17) in breast cancer has been identified. In this review we summarize the experimentally validated targets of up- and downregulated miRNAs and their regulation in breast cancer and bone metastasis for diagnostic and therapeutic purposes.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Jedlinski, Dominik J., Plamena N. Gabrovska, Stephen R. Weinstein, Robert A. Smith und Lyn R. Griffiths. „Single Nucleotide Polymorphism in hsa-mir-196a-2 and Breast Cancer Risk: A Case Control Study“. Twin Research and Human Genetics 14, Nr. 5 (01.10.2011): 417–21. http://dx.doi.org/10.1375/twin.14.5.417.

Der volle Inhalt der Quelle

Annotation:

microRNAs are small, non-coding RNAs that influence gene expression on a post-transcriptional level. They participate in diverse biological pathways and may act as either tumor suppressor genes or oncogenes. As they may have an effect on thousands of target mRNAs, single-nucleotide polymorphisms in microRNA genes might have major functional consequences, because the microRNA's properties and/or maturation may change. miR-196a has been reported to be aberrantly expressed in breast cancer tissue. Additionally, the SNP rs11614913 in hsa-mir-196a-2 has been found to be associated with breast cancer risk in some studies although not in others. This study evaluated the association between rs11614913 and breast cancer risk in a Caucasian case-control cohort in Queensland, Australia. Results do not support an association of the tested hsa-mir-196a-2 polymorphism with breast cancer susceptibility in this cohort. As there is a discrepancy between our results and previous findings, it is important to assess the role of rs11614913 in breast cancer by further larger studies investigating different ethnic groups.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Eichelser, Corinna, Dieter Flesch-Janys, Jenny Chang-Claude, Klaus Pantel und Heidi Schwarzenbach. „Deregulated Serum Concentrations of Circulating Cell–Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression“. Clinical Chemistry 59, Nr. 10 (01.10.2013): 1489–96. http://dx.doi.org/10.1373/clinchem.2013.205161.

Der volle Inhalt der Quelle

Annotation:

BACKGROUND MicroRNAs (miRs) are small, noncoding RNAs that target genes involved in tumor development and progression. In the current study, we investigated the use of circulating miR concentrations as biomarkers in the serum of breast cancer patients. METHODS We analyzed serum samples from 120 patients with primary breast cancer after surgery and before chemotherapy (M0, classified into 3 subgroups of 40 patients with progesterone/estrogen-positive, HER2-positive, and triple-negative cancer), 32 patients with overt metastasis (M1), and 40 healthy women. Using quantitative TaqMan MicroRNA PCR, we measured the relative concentrations of 6 circulating microRNAs (miR-10b, -17, -34a, -93, -155, and -373) known to be relevant for tumor development and progression. The data were correlated with clinicopathologic risk factors, with particular reference to HER2 and hormone receptor status of the primary tumor and the presence of metastases. RESULTS The relative serum concentrations of circulating miR-34a [P = 0.013, area under the curve (AUC) 0.636], miR-93 (P = 0.001, AUC 0.699), and miR-373 (P = 0.0001, AUC 0.879) were significantly different between M0 breast cancer patients and healthy women, whereas miR-17 (P = 0.002, AUC 0.679) and miR-155 (P = 0.0001, AUC 0.781) were differently expressed between M0 and M1 patients. Increased concentrations of miR-373 were associated with negative HER2 status of the primary tumor (P = 0.0001). Deregulated concentrations of miR-17 (P = 0.019) and miR-34a (P = 0.029) were detected in patients with progesterone/estrogen receptor–positive and –negative status, respectively. CONCLUSIONS Our findings indicate that serum concentrations of deregulated microRNAs may be linked to a particular biology of breast carcinomas favoring progression and metastatic spread.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Shao, Bin, Xiaoxia Wang, Lei Zhang, Deyu Li, Xiaoran Liu, Guohong Song, Huiqing Cao, Jun Zhu und Huiping Li. „Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer“. Technology in Cancer Research & Treatment 18 (01.01.2019): 153303381982870. http://dx.doi.org/10.1177/1533033819828709.

Der volle Inhalt der Quelle

Annotation:

Background: MicroRNAs contribute to chemotherapy response in different types of cancer. We hypothesized that plasma miRNAs are potentially associated with chemotherapy response in patients with metastatic breast cancer. Patients and Methods: Fourteen candidate microRNAs were chosen from the literature, and their plasma levels were measured by quantitative polymerase chain reaction (PCR). Forty metastatic breast cancer patients were chosen as the training groups. The potential significant microRNAs were validated in another 103 plasma samples. Results: In the training set, we identified 3 microRNAs (miR-200a, miR-210, and miR-451) as significantly dysregulated miRNAs between sensitive group (partial response (and stable disease) and resistant group (progressive disease). Then, in the validation set, miR-200a (area under the curve = 0.881, sensitivity = 94.1%, specificity = 76.7%) and miR-210 (area under the curve = 0.851, sensitivity = 88.2%, specificity = 72.1%) showed high diagnostic accuracy for distinguishing sensitive group from resistant group. Furthermore, the plasma level of miR-200a was significantly associated with the stage in surgery ( P = .035), and the high level of miR-210 expression was associated with internal organ metastasis (liver, lung, and brain; P = .024). Conclusions: Plasma miR-200a and miR-210 could be effective biomarkers for the prediction of chemotherapy resistance in metastatic breast cancer patients.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kalinina, Tatiana S., Vladislav V. Kononchuk, Alisa K. Yakovleva, Efim Y. Alekseenok, Sergey V. Sidorov und Lyudmila F. Gulyaeva. „Association between Lymph Node Status and Expression Levels of Androgen Receptor, miR-185, miR-205, and miR-21 in Breast Cancer Subtypes“. International Journal of Breast Cancer 2020 (23.04.2020): 1–7. http://dx.doi.org/10.1155/2020/3259393.

Der volle Inhalt der Quelle

Annotation:

Breast cancer is the most commonly diagnosed cancer among women. Difficulties in treating breast cancer are associated with the occurrence of metastases at early stages of disease, leading to its further progression. Recent studies have shown that changes in androgen receptor (AR) and microRNAs’ expressions are associated with mammary gland carcinogenesis, in particular, with the formation of metastases. Thus, to identify novel metastatic markers, we evaluated the expression levels of AR; miR-185 and miR-205, both of which have been confirmed to target AR; and miR-21, transcription of which is regulated by AR, in breast cancer samples (n=89). Here, we show that the molecular subtypes of breast cancer differ in the expression profiles of AR and AR-associated microRNAs. In addition, the expression of AR and these microRNAs may depend on the expression of PR, ER, and HER2 receptors. Our results show that the possibility of using AR and microRNAs as markers depends on the tumor subtype: a decrease in AR expression may be the marker for the presence of lymph node metastases in patients with HER2-positive subtypes of breast cancer, and disturbance of miR-205, miR-185, and miR-21 expressions may be the marker in patients with a luminal B HER2-positive subtype. Cases with metastases in this type of breast cancer are characterized by a higher level of miR-205 and a lower level of miR-185 and miR-21 in tumor tissues compared to nonmetastatic cases. A decrease in the miR-185 level is also associated with lymph node metastasis in luminal B HER2-negative breast cancer. Thus, the expression levels of AR, miR-185, miR-205, and miR-21 can serve as markers to predict cancer spread to the lymph node in luminal B- and HER2-positive subtypes of breast cancer.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wu, Qian, Zuhong Lu, Hailing Li, Jiafeng Lu, Li Guo und Qinyu Ge. „Next-Generation Sequencing of MicroRNAs for Breast Cancer Detection“. Journal of Biomedicine and Biotechnology 2011 (2011): 1–7. http://dx.doi.org/10.1155/2011/597145.

Der volle Inhalt der Quelle

Annotation:

It is reported that different microRNA (miRNA) profiles can be detected in the blood of cancer patients. We investigated that whether the key serum miRNAs could discriminate patients with and without breast cancer. This study was divided into three parts: (1) miRNA marker discovery using SOLiD sequencing-based miRNA profiling on cancerous and adjacent noncancerous breast tissue of one breast cancer patient; (2) marker selection and validation by real-time PCR on a small set of serum; (3) gene ontology analysis of the key miRNA target genes. Of genome-wide tissue miRNA expression analysis, five miRNAs were found to be altered more than fivefold by SOLiD sequencing (i.e., miR-29a, miR-23a, miR-23b, miR-192, and miR-21). All the five miRNAs were validated on the 20 breast cancer patients and 20 controls. miR-29a and miR-21 were significantly increased in the serum of breast cancer patients (). Gene ontology analysis of the target genes revealed enrichment for special biological process categories, that is, signal transduction, development, apoptosis, cell proliferation, and cell adhesion. SOLiD sequencing provides a promising method for cancer-related miRNA profiling. Serum miRNAs may be useful biomarkers for breast cancer detection.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "Breast cancer, microRNAs, miR-106b"

Saygili, Cansaran. „Phenotypical Characterization Of Microrna-106b Overexpression In Mcf10a Breast Cell Line“. Master's thesis, METU, 2013. http://etd.lib.metu.edu.tr/upload/12615544/index.pdf.

Der volle Inhalt der Quelle

Annotation:

MicroRNAs are small non-coding RNAs which regulate gene expression by binding to 3&rsquo
UTR of their target mRNAs. Deregulated expression of microRNAs is detected in many pathologies including different types of cancers. miR-106b, is a member of miR-106b-25 cluster and overexpressed in many cancers including breast cancer. Based on miR-106b overexpression, we hypothesized that miR-106b may be an oncogene candidate. To explore miR-106b related phenotypes, we used an already miR-106b transfected model cell line system. Stably transfected MCF10A cells were investigated for alterations in cell growth, motility, migration and invasion. Our results showed that miR-106b overexpression caused increased growth motility and migration. On the other hand, based on matrigel invasion assay miR-106b expression caused a reduction in cell invasion. Further studies are needed to be performed to understand the precise role of miR-106b in breast cancer. Studies are underway to detect possible miR-106b targets that may help to explain these phenotypical alterations.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Stankevicins, Luiza. „MicroRNAs in Breast Cancer Progression and DNA Damage Response“. Thesis, Paris 11, 2012. http://www.theses.fr/2012PA11T041.

Der volle Inhalt der Quelle

Annotation:

Le cancer du sein est marqué par une grande hétérogénéité. C´est une maladie complexe, fortement influencée par l´environnement pourtant, elle dépend aussi d´une accumulation de mutations génétiques associées à la dérégulation épigénétique des voies clés. Les altérations présentes dans le profil d´expression génique observées dans la tumeur, peuvent être le résultat de mécanismes de régulation des gènes à différent niveaux, comme des modifications post-transcriptionnelles menées par le mécanisme d´ARN d´interférence sous forme de microARN (miARN). Ce mécanisme peut conduire au début et développement du cancer aussi bien qu’à la résistance aux thérapies. Les miARN font partie d’une classe d´ARN non-codants qui ont émergé ces dernières années comme l'un des principaux régulateurs de l'expression des gènes par sa capacité à réguler négativement l'activité des ARN messagers (ARNm). L´importance de cette régulation a été observée par la présence de ce type de contrôle dans plusieurs processus biologiques, parmi eux, des voies liées à la prolifération, différentiation et apoptose. Afin de mieux comprendre les mécanismes d’initiation et progression tumorale dans le cancer du sein, nous avons fait une analyse globale de l´expression des miARN, par la technique de microarray, dans la série de lignées cellulaires 21T. Cette série est un modèle in vitro de la progression tumorale, comprenant la lignée 16N, obtenue à partir de l’épithélium normal infecté par des virus HPV-16, les lignées 21PT et 21NT, qui correspondent au carcinome in situ et les lignées 21MT1 et 21MT2 obtenues à partir d´une effusion pleurale métastatique à l’endroit de la métastase. Etant donné que les miARN jouent un rôle dans la régulation de l´apoptose et d´autres mécanismes de réponse aux dommages fait à l´ADN et que l´irradiation dans des formes différentes est couramment utilisée comme outil diagnostique, par exemple dans des mammographies, nous avons évalué l´expression de miARN après avoir soumis les cellules à des irradiations de haute et basse énergie, et au traitement avec de la doxorubicine. Les tests ont été faits sur les lignées non tumorales (MCF-10A et HB-2) et sur les lignées tumorales (MCF-7 et T-47D). On a pu observer que le rayon X de basse énergie est capable de causer des cassures double brin à l´ADN et de conduire les cellules à l´apoptose. Une légère altération dans les profils d´expression des miARN impliqués dans cette voie, comme let-7a, miR-34a et miR-29b, a aussi été remarquée. En ce qui concerne la réponse aux dommages fait à l´ADN, une upregulation dans l´expression de miR-29b, qui sous des conditions physiologiques normales est régulée négativement, a été observée après les traitements. Le microARNome de la série 21 montre une importante sous-expression de miR-205, un enrichissement du facteur pro-métastatique ZEB-1 et une réduction conséquente dans les niveaux d’e-cadherine, observée par western blot, seulement dans les lignées métastatiques (21MT). L´ensemble des résultats, suggèrent que miR-29b peut être un bio-marqueur potentiel du stress génotoxique et que miR-205 peut participer du processus de transition épithélium-mésenchyme et, en outre, quand il est sous-exprimé, peut augmenter le potentiel métastatique des cellules de la série 21T
Breast tumors are characterized by their high heterogeneity. Breast cancer is a complex disease, which has its development strongly influenced by environmental factors, combined with a progressive accumulation of genetic mutations and epigenetic dysregulation of critical pathways. Changes in gene expression patterns may be a result of a deregulation in epigenetic events as well as in post-transcriptional regulation driven by RNA interference endogenously represented by microRNA (miRNA). These mechanisms are capable to promote the initiation, maintenance and progression of carcinogenesis and are also implicated on the development of therapy resistance. miRNAs form a class of non-coding RNAs, which have emerged in recent years as one of the major regulators of gene expression through its capacity to silence messenger RNAs (mRNAs) containing a partially complementary sequence. The importance of regulation mediated by miRNAs was observed on their ability to regulate a wide range of biological processes, including cell proliferation, differentiation and apoptosis.To gain insights into the mechanisms involved in breast cancer initiation and progression we conducted a miRNA global expression on 21T series that are an in vitro model of breast cancer progression, comprising cell lines derived from the same patient, which include a normal epithelia (16N), primary in situ ductal carcinoma (21PT and 21NT) and cells derived from pleural effusion of lung metastasis (21MT-1 and 21MT-2). Considering the importance of miRNAs in the regulation of apoptosis, and that irradiation in different spectra is commonly used in diagnostic procedures, as mammography and on radiotherapy, we evaluated the miRNA expression after cell low and high energy irradiation and doxorubicin treatment to determine whether miRNAs are useful biomarkers to detect cell response after DNA damage. The experiments were done on the non-tumoral cell lines MCF-10A and HB-2 and on the breast carcinoma derived cell lines MCF-7 and T-47D. We observed that low energy X-rays is able to promote DNA strand breaks and apoptosis and to slightly change the expression of miRNAs involved on this pathway, such as let-7a, miR-34a and miR-29b. Regarding DNA stress response pathways, an upregulation on miR-29b expression, that in normal conditions is downregulated in tumor cell lines could be observed after all treatments. The microRNAome of 21T series revealed a significant downregulation of miR-205, an enrichment of the pro-metastatic factor ZEB-1, potential target for miR-205 and the consequent reduction of e-cadherin levels in 21MT cells checked by western blot. Our results indicate that miR-29b is a possible biomarker of genotoxic stress and that miR-205 can participate on the metastatic potential of 21T cells

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Stankevicins, Luiza da Cunha. „MicroRNAs in breast cancer progression and DNA damage response“. Universidade do Estado do Rio de Janeiro, 2012. http://www.bdtd.uerj.br/tde_busca/arquivo.php?codArquivo=9187.

Der volle Inhalt der Quelle

Annotation:

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Os tumores de mama são caracterizados pela sua alta heterogeneidade. O câncer de mama é uma doença complexa, que possui o seu desenvolvimento fortemente influenciado por fatores ambientais, combinada a uma progressiva acumulação de mutações genéticas e desregulação epigenética de vias críticas. Alterações nos padrões de expressão gênica podem ser resultado de uma desregulação no controle de eventos epigenéticos, assim como, na regulação pós-transcricional pelo mecanismo de RNA de interferência endógeno via microRNA (miRNA). Estes eventos são capazes de levar à iniciação, à promoção e à manutenção da carcinogênese, como também ter implicações no desenvolvimento da resistência à terapia Os miRNAs formam uma classe de RNAs não codificantes, que durante os últimos anos surgiram como um dos principais reguladores da expressão gênica, através da sua capacidade de regular negativamente a atividade de RNAs mensageiros (RNAms) portadores de uma seqüencia parcialmente complementar. A importância da regulação mediada por miRNAs foi observada pela capacidade destas moléculas em regular uma vasta gama de processos biológicos incluindo a proliferação celular, diferenciação e a apoptose. Para avaliar a expressão de miRNAs durante a progressão tumoral, utilizamos como modelo experimental a série 21T que compreende 5 linhagens celulares originárias da mesma paciente diagnosticada com um tumor primário de mama do tipo ErbB2 e uma posterior metástase pulmonar. Essa série é composta pela linhagem obtida a partir do tecido normal 16N, pelas linhagens correspondentes ao carcinoma primário 21PT e 21NT e pelas linhagens obtidas um ano após o diagnóstico inicial, a partir da efusão pleural no sítio metastatico 21MT1 e 21MT2. O miRNAoma da série 21T revelou uma redução significativa nos níveis de miR-205 e nos níveis da proteina e-caderina e um enriquecimento do fator pró-metastático ZEB-1 nas células 21MT. Considerando a importância dos miRNAs na regulação da apoptose, e que a irradiação em diferentes espectros é comumente usada em procedimentos de diagnóstico como mamografia e na radioterapia, avaliamos a expressão de miRNAs após irradiação de alta e baixa energia e do tratamento doxorrubicina. Para os ensaios foram utilizados as linhagens não tumorais MCF-10A e HB-2 e as linhagens de carcinoma da mama MCF-7 e T-47D. Observou-se que raios-X de baixa energia são capazes de promover quebras na molécula do DNA e apoptose assim como, alterar sensivelmente miRNAs envolvidos nessas vias como o let-7a, miR-34a e miR-29b. No que diz respeito à resposta a danos genotóxicos, uma regulação positiva sobre a expressão de miR-29b, o qual em condições normais é regulado negativamente foi observada uma regulação positiva sobre miR-29b expressão após todos os tratamentos em células tumorais. Nossos resultados indicam que miR-29b é um possível biomarcador de estresse genotóxico e que miR-205 pode participar no potencial metastático das células 21T.
Breast tumors are characterized by their high heterogeneity. It is a complex disease, which has its development strongly influenced by environmental factors, combined with a progressive accumulation of genetic mutations and epigenetic dysregulation of critical pathways. Changes in gene expression patterns may be a result of a deregulation in epigenetic events as well as in post-transcriptional regulation driven by RNA interference endogenously represented by microRNA (miRNA) these mechanisms are capable to promote the initiation, maintenance and progression of carcinogenesis; they are also implicated on the development of therapy resistance. miRNAs form a class of non-coding RNAs which have emerged in recent years as one of the major regulators of gene expression through its capacity to silence messenger RNAs (mRNAs) containing a partially complementary sequence. The importance of regulation mediated by miRNAs was observed on their ability to regulate a wide range of biological processes including cell proliferation, differentiation and apoptosis.To gain insights into the mechanisms involved in breast cancer initiation and progression conducted a miRNA global expression on 21T series that are an in vitro model of breast cancer progression comprising cell lines derived from the same patient which include a normal epithelia (16N), primary in situ ductal carcinoma (21PT and 21NT) and cells derived from pleural effusion of lung metastasis (21MT-1 and 21MT-2). Considering the importance of miRNAs in the regulation of apoptosis, and that irradiation in different spectra is commonly used in diagnostic procedures as mammography and on radiotherapy, we evaluate the miRNA expression after cell low and high energy irradiation and doxorubicin treatment to determine whether miRNAs are useful biomarkers to detect cell response after DNA damage. The experiments were done on the non-tumoral cell lines MCF-10A and HB-2 and on the breast carcinoma derived cell lines MCF-7 and T-47D. We observed that of low energy X-rays is able to promote DNA strand breaks and apoptosis and to slightly change the expression of miRNAs involved on this pathway such as let-7a, miR-34a and miR-29b. Regarding DNA stress response pathways an upregulation on miR-29b expression, that in normal conditions is downregulated in tumor cell lines could be observed after all treatments. The microRNAome of 21T series revealed a significant downregulation of miR-205, an enrichment of the prometastatic factor ZEB-1, potential target for miR-205 and the consequent reduction of ecadherin levels in 21MT cells checked by western blot. Our results indicate that miR-29b is biomarkers of genotoxic stress and that miR-205can participate on the metastatic potential of 21T cells.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Heyn, Holger. „Identification of microRNAs miR-203 and miR-335 forming a network of regulation in breast cancer development“. Hannover Technische Informationsbibliothek und Universitätsbibliothek Hannover, 2010. http://d-nb.info/1004000561/34.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Heyn, Holger [Verfasser]. „Identification of microRNAs miR-203 and miR-335 forming a network of regulation in breast cancer development / Holger Heyn“. Hannover : Technische Informationsbibliothek und Universitätsbibliothek Hannover, 2010. http://d-nb.info/1004000561/34.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Tuna, Serkan. „Functional Characterization Of Microrna-125b Expression In Mcf7 Breast Cancer Cell Line“. Master's thesis, METU, 2010. http://etd.lib.metu.edu.tr/upload/12612434/index.pdf.

Der volle Inhalt der Quelle

Annotation:

microRNA dependent gene expression regulation has roles in diverse processes such as differentiation, proliferation and apoptosis. Therefore, deregulated miRNA expression has functional importance for various diseases, including cancer. miR-125b is among the commonly downregulated miRNAs in breast cancer cells . Therefore we aimed to characterize the effects of miR-125b expression in MCF7 breast cancer cell line (BCCL) to better understand its roles in tumorigenesis. Here, we investigated mir-125 family members

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zalles, Nicole. „Effects of MicroRNA modulation of PLK1 in Breast Cancer in combination with PLK1 inhibitor NMS-P937“. The Ohio State University, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1554130079416561.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Sánchez-Cid, Pérez Lourdes. „Análisis de los perfiles de expresión de microRNAs en cáncer de mama y de la implicación de la familia miR-200 en metástasis“. Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/402827.

Der volle Inhalt der Quelle

Annotation:

Esta tesis consiste en el estudio de la regulación por microRNAs del proceso de metástasis de carcinomas ductales invasivos de mama. Hemos encontrado una expresión alterada de varios microRNAs en muestras tumorales, incluyendo las familia miR-200 y miR-181, miR-210, miR-101 y miR-10b, a lo largo de la progresión desde tumores primarios a metástasis regionales y a distancia. miR-7, miR-30, miR-148 y miembros de la familia let-7 se encontraron diferencialmente expresados entre tumores primarios no metastáticos vs primarios metastáticos a ganglios linfáticos. Además, los miembros del cluster 1 de la familia miR-200 se econtraban sobreexpresados en las metástasis ganglionares, las cuales mantenían o tenían una expresión más elevada de E-cadherina respecto de sus correspondientes tumores primarios. Adicionalmente y de acuerdo con la tendencia observada en los tejidos tumorales, observamos niveles elevados de miR-200b y miR-7 en la sangre de pacientes con metástasis regional o a distancia en comparación con pacientes con tumores primarios no metastáticos en el momento del diagnóstico. Centrándonos en la significación biológica de la mayor expresión de los miembros de la familia miR-200 en asociación con la progresión metastática, utilizamos el modelo celular MCF10CA1h para inducir la expresión de miR-200. Observamos que miR-200 promovía una transición mesénquima-epitelio que conllevaba la inducción de un marcado programa epitelial. Éste era acompañado de un fuerte incremento de la actividad aldehido deshidrogenasa (ALDH), mayor capacidad de crecimiento en mamoesferas y la transición de un immunofenotipo CD44+ CD24- a CD44+ CD24+, lo cual era indicativo de la adquisición de características de progenitor luminal por parte de células que expresaban miR-200. Además, las células MCF10CA1h que expresaban miR-200 desarrollaron la capacidad de diferenciarse y organizarse en estructuras tubuloalveolares ramificadas similares a las de la mama normal. Se observó además una mayor capacidad de crecimiento tumoral y de colonización metastática in vivo. Además de la expresión de marcadores epiteliales, la expresión de miR-200 resultó en la inducción de la expresión de marcadores basales y de diferenciación luminal in vitro y de forma más prominente in vivo. Todo ello refueza la idea de que miR-200 induce características de progenitor luminal así como de agresividad en células tumorales mamarias. A nivel mecanístico encontramos que la mayor capacidad de autorrenovación promovida por miR-200 era debida en parte a la inhibición de su ya conocidad diana ZEB2 así como de una activación de la ruta de señalización PI3K-AKT. Finalmente, la morfología de los tumores formados in vivo por células que expresaban miR-200 recordaba a la de los carcinomas metaplásicos mamarios, por lo que decidimos estudiarlos. De hecho, observamos que el componente epitelial de tumores metaplásicos expresaban niveles significativamente superiores de miR-200 que el componente mesenquimal y además, mostraban un perfil de marcadores compatible con el de células luminales progenitoras. En vista de los resultados, proponemos que los microRNAs de la familia miR-200 inducen características de células progenitoras luminales, las cuales asociadas a un fenotipo epitelial, promueven la capacidad metastática de las células tumorales.
The maintenance of an epithelial gene program is essential for the metastatic growth of epithelial cancers, including breast cancer. However, little is known of the molecular and cellular mechanisms leading to the enhanced proliferative and survival properties of metastatic epithelial cells. We report here that forced expression of miR-200s in MCF10CA1h mammary cells induced not only a strong epithelial program but also aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures while promoting orthotopic tumor growth and lung colonization in vivo. This was accompanied with the expression of luminal differentiation markers in vitro and in vivo, the overall phenotype being compatible with a promotion of luminal progenitor traits. Interestingly, the morphology of tumors formed in vivo by MCF10CA1h cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC) and the epithelial components of MBC samples expressed significantly higher levels of miR-200s than their mesenchymal components and displayed a marker profile compatible with luminal progenitor cells. Additionally, the miR-200 family showed enhanced expression along progression of invasive ductal breast cancer (IDC) from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b in patients with regional or distant metastases relative to patients with primary node-negative tumors. We propose that the expression of epithelial gene programs through miR-200 family microRNAs promote traits of highly proliferative mammary luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Beldiman, Cornelia. „Role of miR-205 in Breast Cancer Development“. Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T094.

Der volle Inhalt der Quelle

Annotation:

Au cours de ma thèse, j’ai étudié la contribution de miR-205 dans le développement du cancer du sein. MiR-205 a été choisi suite à l'analyse comparative de l'expression du miRome entre la lignée « normale » MCF10A et une lignée cancéreuse dérivée MCF10A-CA1a. J’ai démontré que l’expression de miR-205 augmente durant la tumorigenèse tandis que miR-205 est non détectable dans la lignée cellulaire ayant un potentiel métastatique. De plus, j’ai montré que les cellules souches du cancer du sein expriment miR-205, contrairement à la population non souche. En utilisant des cultures de cellules épithéliales 3D, j’ai corrélé la fonction tumorigène de miR-205 à la répression de l'apoptose et non à une prolifération accrue. De plus, le niveau d'expression de la E-Cadhérine dépend de la quantité de miR-205 dans les différentes lignées cellulaires de MCF10A. Les études de perte de fonction suggèrent que la E-Cadhérine est impliquée dans le phénotype acini miR-205-Dépendant, en corrélation avec la transformation de cellules épithéliales du sein. L’ensemble de ces résultats met en lumière la complexité et la duplicité des miRNA durant le processus de cancérisation. Ce type d’étude ouvre des perspectives d’utilisation des miRNA dans le cadre des diagnostics et/ou thérapeutiques
During the time I was working on my thesis, I aimed to understand the role of miR-205 in breast cancer development. MiR-205 was chosen from the comparative analysis of total micro-RNAs expression in non-Transformed and tumorigenic cell lines of the MCF10A breast epithelial cell model. I demonstrated the complexity of miR-205 functions during breast epithelial cell transformation by showing miR-205 overexpression in transformed non-Invasive cell lines and miR-205 down-Regulation in cell line with metastatic potential. Moreover, we demonstrated increased level of miR-205 expression in breast cancer stem cells in comparison with non-Stem cells. Using 3D cultures of breast epithelial cells, I succeeded to correlate the tumorigenic function of miR-205 with its role in modulation of acinar size, and to attribute it to the apoptosis repression but not increased proliferation. Further, I was able to show that miR-205 exercises its oncogenic functions via targeting ZEB1, an inhibitor of E-Cadherin. Indeed, E-Cadherin expression level depends on the amount of miR-205 in different MCF10A cell lines. Downregulating E-Cadherin restored normal acinar morphology in miR-205 expressing cells, consistent with E-Cadherin being involved in the miR-205-Dependent acini phenotype that correlates with tumorigenic breast epithelial cell transformation

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Cheung, Douglas Guy. „Action of CDK Inhibitor PHA-848125 in ER-negative Breast Cancer with MicroRNA-221/222 Overexpression“. The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu150054220454799.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Konferenzberichte zum Thema "Breast cancer, microRNAs, miR-106b"

Zavala, Valentina, Wanda Fernandez, Adolfo Cruz, Laura Segovia, Mauricio Camus und Pilar Carvallo. „Abstract 1850: BRCA1-regulating microRNAs, miR-146a and miR-638, are overexpressed in triple negative breast cancer tumors.“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1850.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Young, JS, T. Kawaguchi, L. Yan, Q. Qi, S. Liu und K. Takabe. „Abstract P5-07-08: Survival relevance of tamoxifen sensitivity-related microRNAs, miR-342 and miR-221/222, in breast cancer patients“. In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p5-07-08.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Goldberger, Natalie E., Chang Hee Kim, Renard Walker und Kent Hunter. „Abstract 3988: Identification of miR-132 and miR-290-3p as putative tumor and metastasis suppressor microRNAs in breast cancer“. In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3988.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Manavalan, Tissa T., und Carolyn M. Klinge. „Abstract 1096: Loss of miR-200 family of microRNAs confers resistance to tamoxifen in human breast cancer cells“. In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1096.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Pan, S., F. Yu, C. Gong und E. Song. „Tumor Invasion and Metastasis Initiated by mir-106b in Breast Cancer by Targeting BRMS1 and RB.“ In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-6157.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Tan, W., G. Liang, X. Xie, L. Tan, AJ Sanders, Z. Liu, Y. Ling, W. Zhong, WG Jiang und C. Gong. „Abstract P6-09-07: Expression of miR-106b in circulating tumor cells is associated with EMT and prognosis in metastatic breast cancer patients“. In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-09-07.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Huang, Jing, Eric A. Collisson, Bill Gibb, Lakshmi Jakkula, Steven Martin und Joe w. Gray. „Abstract 1948: Pvt1-encoded microRNA miR-1204 in tumorigenesis of human ovarian and breast cancer“. In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1948.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Parra, Columba de la, Linette Castillo-Pichardo, Luis A. Cubano, George A. Calin und Suranganie Dharmawardhane. „Abstract A057: Therapeutic potential of genistein via targeting the microRNA miR-155 in breast cancer“. In Abstracts: AACR Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications - October 3-6, 2013; San Diego, CA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1557-3125.advbc-a057.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Xu, Z., X. Wang und L. Fang. „Abstract P4-07-19: MicroRNA miR-24 enhances tumor angiogenesis and metastasis in breast cancer“. In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p4-07-19.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Debeb, Bisrat G., Lara Lacerda, Simone Anfossi, Parmeswaran Diagaradjane, Khoi Chu, Lei Huo, Caimiao Wei et al. „Abstract P6-16-01: The microRNA miR-141 is a key regulator of brain metastasis from breast cancer“. In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-16-01.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!